Original Contribution
Arsenic Trioxide in Recurrent Urothelial Cancer: A Cancer and Leukemia Group B Phase II Trial (CALGB 99903)

https://doi.org/10.3816/CGC.2009.n.026Get rights and content

Abstract

Background

Arsenic trioxide is highly active in patients with acute promyelocytic leukemia. There are also preclinical data to suggest that this drug might be active in nonhematopoietic malignancies, and transitional cell carcinoma cell lines are particularly sensitive to this agent.

Patients and Methods

Twelve evaluable patients with metastatic urothelial cancer were treated with arsenic trioxide in a phase II trial conducted by the Cancer and Leukemia Group B. Eligible patients were required to have measurable urothelial cancer and a maximum of 1 previous chemotherapy regimen. Arsenic trioxide was given at a dose of 0.3 mg/kg daily for 5 days every 28 days.

Results

No major responses were observed; 4 patients achieved stable disease. The median survival was 6.5 months (95% CI, 3.9–13.4 months). The most commonly observed toxicities included fatigue and malaise, anemia, nausea, emesis, and constipation.

Conclusion

Arsenic trioxide at this dose and schedule does not have significant activity in previously treated urothelial cancer and has substantial toxicity in this patient population.

References (13)

There are more references available in the full text version of this article.

This article might include the discussion of investigational and/or unlabeled uses of drugs and/or devices that might not be approved by the FDA.

Electronic forwarding or copying is a violation of US and international copyright laws.

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1558-7673, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. www.copyright.com 978-750-8400.

View full text